Nektar Therapeutics (NASDAQ:NKTR) saw its stock soar 140% following promising Phase 2b trial results for its experimental treatment rezpegaldesleukin in moderate-to-severe atopic dermatitis.
The biotech company reported that all three dosage groups of rezpegaldesleukin achieved statistically significant improvements in the primary endpoint, which measured the average percentage change in EASI scores at week 16 versus placebo. The drug also met several key secondary endpoints, including EASI-75, EASI-50, and reductions in the affected body surface area.
The highest dosage (24 µg/kg every two weeks) produced a 61% average improvement in EASI scores, with 42% of patients reaching EASI-75, reflecting a minimum 75% decrease in disease severity. Rapid symptom relief was noted, including improvements in skin clearance and itch reduction.
“These data from REZOLVE-AD show a fast onset of both EASI response and itch relief within the first few doses of rezpegaldesleukin treatment, which are important metrics for physicians as they assess treatment options in atopic dermatitis,” said Professor Jonathan Silverberg of George Washington University.
Nektar confirmed that the safety profile remained consistent with earlier trials. Injection site reactions were the most common adverse event, reported in 69.7% of patients. Unlike some competitors, rezpegaldesleukin did not increase risks of conjunctivitis, oral ulcers, or infections.
The company intends to proceed with the long-term maintenance phase of the study, expecting results by early 2026. Additionally, Phase 2b data for rezpegaldesleukin in alopecia areata is anticipated in late 2025.